Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.53
Bid: 1.53
Ask: 1.60
Change: -0.002 (-0.13%)
Spread: 0.07 (4.575%)
Open: 1.53
High: 1.53
Low: 1.53
Prev. Close: 1.567
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Challenger Energy hails Saffron-2 well; SDCL placing

Thu, 02nd Sep 2021 21:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Challenger Energy Group PLC - oil and gas producer in the Caribbean - Considers development of the Saffron-2 well to be economically justified, based on current production rates. Work is underway to update the geological and reservoir model with the results of Saffron-2. Talks with Arena Investors LP over funding continue. Challenger is investigating farm-out options and reserve based lending options. Challenger does not expect to issue further convertible loan notes under the facility that expired in July.

----------

Premier African Minerals PLC - metals and rare earths miner - Encounters visible spodumene mineralisation at the Zulu lithium and tantalum project in Zimbabwe. First assay results from the project are expected this month, and a third rig is expected in October.

----------

Good Energy Group PLC - Chippenham-based renewable energy utility - Holders of 27% of shares have accepted Ecotricity Group Ltd's 340p-per-share takeover offer, including the 25% already owned by Ecotricity. The offer remains open for acceptance.

----------

Oracle Power PLC - coal miner in Pakistan and gold explorer in Western Australia - Receives conversion notice for a further GBP100,000 of the GBP1.5 million share subscription announced in July 2020. Oracle will issue 31.3 million shares. GBP400,000 remains outstanding for conversion under the subscription.

----------

Active Energy Group PLC - London-based biomass fuel producer - Results from an independent analysis show that Active Energy's CoalSwitch pellets are superior to white pellets, producing less ash, less carbon and more heat.

----------

Sensyne Health PLC - Oxford-based healthcare software developer - Signs five-year research agreement with Great Ormond Street Hospital in London to analyse anonymised patient data using clinical artificial intelligence. The agreement focuses on paediatric drug discovery, clinical decision support tools and clinical trial design.

----------

Hemogenyx Pharmaceuticals PLC - London-based blood disease drug developer - Patent application, titled "Monocloncal Antibodies to Human FLT3/FLK2 Receptor Protein", approved in the US. The patent is another important step in develping Hemogenyx's intellectual property and protecting its drug candidates, company says.

----------

Tiziana Life Sciences PLC - London-based cancer drug developer - Signs licence deal with Precision Biosciences Inc, a Durham, North Carolina-based company developing CAR T-cell therapies. The two companies will explore whether Tiziana's foralumab can improve the outcome of CAR T-cell therapy. "Precision will be responsible for the development, commercialization, and costs for use of foralumab, and Tiziana will receive upfront payment, certain milestone payments, and royalties," Tiziana says.

----------

SDCL Energy Efficiency Income Trust PLC - investor in energy infrastructure - Plans to issue 158.4 million shares at 110.5 pence each, a 6.0% discount to the Wednesday closing price, through an open offer, placing, offer for subscription and intermediaries offer. That would raise around GBP175 million. The money will be used to invest in a pipeline of opportunities worth over GBP200 million.

----------

Zephyr Energy PLC - oil and gas explorer in the Rocky Mountain region - Test results from the State 16-2LN-CC well in the Paradox Basin, Utah, provide strong evidence of the potential to develop the Cane Creek reservoir as a hydraulically stimulated resource play. Final well completion design work is underway and the company has secured equipment and a completion crew. Production testing will start in October and initial flow test results are expected by the end of that month.

----------

Goldstone Resources Ltd - gold explorer in Ghana, Senegal and Gabon - Deadline to pay interest on a loan from Asia Investments Management Services Ltd is further extended to September 19. Interest will continue to accrue at a 17% rate. Goldstone is in talks with AIMS to reschedule and restructure the loan.

----------

SolGold PLC - gold and copper explorer in Ecuador - Exploration drilling at the Rio Amarillo project is underway. Hole 1 returned encouraging surface rock-saw channel sample results. "The regional geological setting and gross geological architecture at Rio Amarillo is very impressive," Technical Services Manager Benn Whistler says.

----------

Empyrean Energy PLC - oil and gas explorer in China, Indonesia and California - Awards integrated drilling contract for the Jade prospect offshore China to China Oilfield Services Ltd. COSL's drilling cost estimate of USD12.3 million is lower than the previous estimate for USD18.5 million. Well spud date target set for December 15 to December 30.

----------

Supply@Me Capital PLC - London-based inventory monetisation services provider - Agrees a 12-month loan facility provided by ARC Group. The facility includes an initial tranche of GBP5 million, with a further GBP2 million available within 60 days, at an interest rate of 10%. Warrants will be issued for 20% of the total value. The facility will replace the subscription agreement with Negma Group Ltd, and the remaining GBP2.1 million in convertible bonds held by Negma will be repaid in cash. Supply@Me continues to explore a Nasdaq listing.

----------

Corcel PLC - battery metals explorer in Papua New Guinea - Extends the dates by which Resource Mining Corp Ltd has to repay its debt of AUD4.8 million, around GBP2.5 million. The first AUD2.8 million is now due on October 31 instead of September 30. The remainder continues to be due on January 14. This is to allow Resource Mining time to hold its general meeting, following Corcel's acquisition of the Wo Wo Gap nickel-cobalt project from Resource Mining. As consideration for the acquisition, Corcel is "releasing all liabilities and obligations" in connection with the debt.

----------

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Sep 2023 19:43

IN BRIEF: Hemogenyx Pharmaceuticals says patent number published

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for blood diseases - Says its patent application number "WO2023168292 Chimeric Bait Receptors and Uses Thereof" was published by the World Intellectual Property Organization on Thursday. Says it remains to be reviewed and approved by national patent authorities.

Read more
10 Jul 2023 10:27

Hemogenyx says Hemo-Car-T treatment placed on clinical hold by US FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it has received a review letter from the US Food & Drug Administration confirming its placement of Hemo-Car-T on clinical hold.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
2 Jun 2023 13:08

IN BRIEF: Hemogenyx announces clinical hold for Hemo-Car-T treatment

Hemogenyx Pharmaceuticals PLC -hemo London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Notes receipt of notice from the US Food & Drug Administration over its investigational new drug application for its product candidate Chimeric Antigen Receptor T-cells, or Hemo-Car-T. Says Hemo-Car-T is a treatment for acute myeloid leukemia. Says FDA put Hemo-Car-T on clinical hold, pending an FDA letter to be received within 30 days detailing what additional information needs to be provided by Hemogenyx. Hemogenyx submitted the investigational new drug application in early May, seeking authorisation to begin a phase 1 clinical trial of Hemo-Car-T.

Read more
9 May 2023 15:16

IN BRIEF: Hemogenyx submits FDA application for Hemo-Car-T treatment

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Submits investigational new drug application seeking authorisation from the US Food & Drug Administration to begin a phase 1 clinical trial of its lead product chemic antigen receptor T-cells, or Hemo-Car-T, for treating acute myeloid leukemia.

Read more
28 Apr 2023 15:35

EARNINGS SUMMARY: DP Aircraft profit swing, Chesterfield loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
23 Mar 2023 20:32

TRADING UPDATES: Fragrant Prosperity to buy Hi 55, Oscillate talks end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday not separately reported by Alliance News:

Read more
26 Jan 2023 10:45

Hemogenyx raises GBP4 million in share placing for Hemo-CAR-T product

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it successfully raised GBP4.1 million in a placing of new shares, with the fresh cash to be used to progress its Hemo-CAR-T product candidate into clinical trials.

Read more
23 Jan 2023 16:59

IN BRIEF: Hemogenyx completes process run for HEMO-CAR-T manufacture

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Completes third process qualification run for the manufacture of HEMO-CAR-T cells. Says the HEMO-CAR-T cells will be tested by third party to ensure quality. The three process runs are required by the US Food & Drug Administration to begin clinical trials. Following completion of all tests across all PQ runs, data will be compiled for inclusion in the investigational new drug submission pack. HEMO-CAR-T cells are being developed the potential treatment of acute myeloid leukemia, a blood and bone marrow cancer.

Read more
9 Jan 2023 10:21

Hemogenyx shares up on single target protein virus treatment finding

(Alliance News) - Hemogenyx Pharmaceuticals PLC shares jumped early Monday, after the company announced the discovery of a single target protein for use against multiple dangerous viruses.

Read more
4 Jan 2023 11:12

IN BRIEF: Hemogenyx Pharma second process qualification run successful

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Successfully completes its second process qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The company says it was followed by analytical release tests to verify the quality of the manufactured cells. The run is the second of three identical manufacturing runs required by the US Food and Drug Administration for the submission of an investigational new drug application. The IND application is needed in order to commence phase one clinical trials of HEMO-CAR-T cells.

Read more
4 Jan 2023 10:36

SMALL-CAP WINNERS & LOSERS: HeiQ drops on expectation of lower sales

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday.

Read more
18 Nov 2022 16:21

Hemogenyx makes final development run of HEMO-CAR-T cell manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said it has completed the final development run for its manufacturing process of HEMO-CAR-T cells.

Read more
29 Sep 2022 15:09

EARNINGS UPDATES: Hemogenyx hopes on cancer drug; IDE loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Aug 2022 09:50

Hemogenyx wins patent for bi-specific antibody method in China

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it has been awarded a patent for its bi-specific antibody in China.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.